Hepatitis B viral X protein interacts with tumor suppressor adenomatous polyposis coli to activate Wnt/β-catenin signaling

Cancer Letters

Volumn 300, Issue 2, 2011, Pages 162-172

  Hsieh, Antony ^a   Kim, Hyeon Seop ^a   Lim, Seung Oe ^a   Yu, Dae Yeul ^b   Jung, Guhung ^a  

^a Seoul National University   (South Korea)

^b Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

Author keywords

Catenin; Adenomatous polyposis coli; Hepatitis B viral X protein; Hepatitis B virus; Hepatocellular carcinoma; Wnt

Indexed keywords

BETA CATENIN; CURCUMIN; MYC PROTEIN; PROTEIN X; QUERCETIN; UVOMORULIN; VIRUS PROTEIN; WNT PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; COLON POLYPOSIS; CONTROLLED STUDY; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE REPRESSION; GENE TARGETING; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; NONHUMAN; PHYLOGENY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DETERMINATION; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TRANSACTIVATION; UPREGULATION;

ADENOMATOUS POLYPOSIS COLI PROTEIN; ANIMALS; BETA CATENIN; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LIVER NEOPLASMS; MASS SPECTROMETRY; MICE; MICE, TRANSGENIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANS-ACTIVATORS; TRANSCRIPTIONAL ACTIVATION; WNT PROTEINS;

HEPATITIS B VIRUS;

EID: 78649636204     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.09.018     Document Type: Article

References (40)

1. Farazi P.A., DePinho R.A. Hepatocellular carcinoma pathogenesis: from genes to environment. Nat. Rev. Cancer 2006, 6:674-687.
2. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M.J. Cancer statistics. CA Cancer J. Clin. 2008, 58:71-96.
3. Arii S., Yamaoka Y., Futagawa S., Inoue K., Kobayashi K., Kojiro M., Makuuchi M., Nakamura Y., Okita K., Yamada R. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. the liver cancer study group of Japan. Hepatology 2000, 32:1224-1229.
4. Tanaka S., Arii S. Molecularly targeted therapy for hepatocellular carcinoma. Cancer Sci. 2009, 100:1-8.
5. Whittaker S., Marais R., Zhu A.X. The role of signaling pathways in the development and treatment of hepatocellular carcinoma. Oncogene 2010, 29:4989-5005.
6. Ahn S.H., Park Y.N., Park J.Y., Chang H.Y., Lee J.M., Shin J.E., Han K.H., Park C., Moon Y.M., Chon C.Y. Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. J. Hepatol. 2005, 42:188-194.
7. Tiollais P., Pourcel C., Dejean A. The hepatitis B virus. Nature 1985, 317:489-495.
8. Nguyen D.H., Ludgate L., Hu J. Hepatitis B virus-cell interactions and pathogenesis. J. Cell Physiol. 2008, 216:289-294.
9. Tang H., Oishi N., Kaneko S., Murakami S. Molecular functions and biological roles of hepatitis B virus x protein. Cancer Sci. 2006, 97:977-983.
10. Kim H., Lee Y.H., Won J., Yun Y. Through induction of juxtaposition and tyrosine kinase activity of Jak1, X-gene product of hepatitis B virus stimulates Ras and the transcriptional activation through AP-1, NF-kappaB, and SRE enhancers. Biochem. Biophys. Res. Commun. 2001, 286:886-894.
11. Grigoryan T., Wend P., Klaus A., Birchmeier W. Deciphering the function of canonical Wnt signals in development and disease: conditional loss- and gain-of-function mutations of beta-catenin in mice. Genes Dev. 2008, 22:2308-2341.
12. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell 2006, 127:469-480.
13. Porfiri E., Rubinfeld B., Albert I., Hovanes K., Waterman M., Polakis P. Induction of a beta-catenin-LEF-1 complex by wnt-1 and transforming mutants of beta-catenin. Oncogene 1997, 15:2833-2839.
14. Morin P.J., Sparks A.B., Korinek V., Barker N., Clevers H., Vogelstein B., Kinzler K.W. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science 1997, 275:1787-1790.
15. Satoh S., Daigo Y., Furukawa Y., Kato T., Miwa N., Nishiwaki T., Kawasoe T., Ishiguro H., Fujita M., Tokino T., Sasaki Y., Imaoka S., Murata M., Shimano T., Yamaoka Y., Nakamura Y. AXIN1 mutations in hepatocellular carcinomas, and growth suppression in cancer cells by virus-mediated transfer of AXIN1. Nat. Genet. 2000, 24:245-250.
16. Fodde R., Kuipers J., Rosenberg C., Smits R., Kielman M., Gaspar C., van Es J.H., Breukel C., Wiegant J., Giles R.H., Clevers H. Mutations in the APC tumour suppressor gene cause chromosomal instability. Nat. Cell Biol. 2001, 3:433-438.
17. Fodde R. The APC gene in colorectal cancer. Eur. J. Cancer 2002, 38:867-871.
18. Aoki K., Taketo M.M. Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene. J. Cell Sci. 2007, 120:3327-3335.
19. Suzuki T., Yano H., Nakashima Y., Nakashima O., Kojiro M. Beta-catenin expression in hepatocellular carcinoma: a possible participation of beta-catenin in the dedifferentiation process. J. Gastroenterol. Hepatol. 2002, 17:994-1000.
20. de La Coste A., Romagnolo B., Billuart P., Renard C.A., Buendia M.A., Soubrane O., Fabre M., Chelly J., Beldjord C., Kahn A., Perret C. Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc. Natl. Acad Sci. USA 1998, 95:8847-8851.
21. Cha M.Y., Kim C.M., Park Y.M., Ryu W.S. Hepatitis B virus X protein is essential for the activation of Wnt/beta-catenin signaling in hepatoma cells. Hepatology 2004, 39:1683-1693.
22. Ding Q., Xia W., Liu J.C., Yang J.Y., Lee D.F., Xia J., Bartholomeusz G., Li Y., Pan Y., Li Z., Bargou R.C., Qin J., Lai C.C., Tsai F.J., Tsai C.H., Hung M.C. Erk associates with and primes GSK-3beta for its inactivation resulting in upregulation of beta-catenin. Mol. Cell 2005, 19:159-170.
23. Jung J.K., Kwun H.J., Lee J.O., Arora P., Jang K.L. Hepatitis B virus X protein differentially affects the ubiquitin-mediated proteasomal degradation of beta-catenin depending on the status of cellular p53. J. Gen. Virol. 2007, 88:2144-2154.
24. Gu J.M., Lim S.O., Oh S.J., Yoon S.M., Seong J.K., Jung G. HBx modulates iron regulatory protein 1-mediated iron metabolism via reactive oxygen species. Virus Res. 2008, 133:167-177.
25. Yu D.Y., Moon H.B., Son J.K., Jeong S., Yu S.L., Yoon H., Han Y.M., Lee C.S., Park J.S., Lee C.H., Hyun B.H., Murakami S., Lee K.K. Incidence of hepatocellular carcinoma in transgenic mice expressing the hepatitis B virus X-protein. J. Hepatol. 1999, 31:123-132.
26. Lim S.O., Gu J.M., Kim M.S., Kim H.S., Park Y.N., Park C.K., Cho J.W., Park Y.M., Jung G. Epigenetic changes induced by reactive oxygen species in hepatocellular carcinoma: methylation of the E-cadherin promoter. Gastroenterology 2008, 135:2128-2140. e2121-2128.
27. Lee Y.H., Yun Y. HBx protein of hepatitis B virus activates Jak1-STAT signaling. J. Biol. Chem. 1998, 273:25510-25515.
28. Tang H., Delgermaa L., Huang F., Oishi N., Liu L., He F., Zhao L., Murakami S. The transcriptional transactivation function of HBx protein is important for its augmentation role in hepatitis B virus replication. J. Virol. 2005, 79:5548-5556.
29. Waris G., Huh K.W., Siddiqui A. Mitochondrially associated hepatitis B virus X protein constitutively activates transcription factors STAT-3 and NF-kappa B via oxidative stress. Mol. Cell Biol. 2001, 21:7721-7730.
30. Eklof Spink K., Fridman S.G., Weis W.I. Molecular mechanisms of beta-catenin recognition by adenomatous polyposis coli revealed by the structure of an APC-beta-catenin complex. EMBO J. 2001, 20:6203-6212.
31. Park C.H., Hahm E.R., Park S., Kim H.K., Yang C.H. The inhibitory mechanism of curcumin and its derivative against beta-catenin/Tcf signaling. FEBS Lett. 2005, 579:2965-2971.
32. Pahlke G., Ngiewih Y., Kern M., Jakobs S., Marko D., Eisenbrand G. Impact of quercetin and EGCG on key elements of the Wnt pathway in human colon carcinoma cells. J. Agric. Food Chem. 2006, 54:7075-7082.
33. He T.C., Sparks A.B., Rago C., Hermeking H., Zawel L., da Costa L.T., Morin P.J., Vogelstein B., Kinzler K.W. Identification of c-MYC as a target of the APC pathway. Science 1998, 281:1509-1512.
34. Yook J.I., Li X.Y., Ota I., Fearon E.R., Weiss S.J. Wnt-dependent regulation of the E-cadherin repressor snail. J. Biol. Chem. 2005, 280:11740-11748.
35. Moon E.J., Jeong C.H., Jeong J.W., Kim K.R., Yu D.Y., Murakami S., Kim C.W., Kim K.W. Hepatitis B virus X protein induces angiogenesis by stabilizing hypoxia-inducible factor-1alpha. FASEB J. 2004, 18:382-384.
36. Tanaka Y., Kanai F., Ichimura T., Tateishi K., Asaoka Y., Guleng B., Jazag A., Ohta M., Imamura J., Ikenoue T., Ijichi H., Kawabe T., Isobe T., Omata M. The hepatitis B virus X protein enhances AP-1 activation through interaction with Jab1. Oncogene 2006, 25:633-642.
37. Pang R., Lee T.K., Poon R.T., Fan S.T., Wong K.B., Kwong Y.L., Tse E. Pin1 interacts with a specific serine-proline motif of hepatitis B virus X-protein to enhance hepatocarcinogenesis. Gastroenterology 2007, 132:1088-1103.
38. Kim S.Y., Kim J.C., Kim J.K., Kim H.J., Lee H.M., Choi M.S., Maeng P.J., Ahn J.K. Hepatitis B virus X protein enhances NFkappaB activity through cooperating with VBP1. BMB Rep. 2008, 41:158-163.
39. Yamashita T., Ji J., Budhu A., Forgues M., Yang W., Wang H.Y., Jia H., Ye Q., Qin L.X., Wauthier E., Reid L.M., Minato H., Honda M., Kaneko S., Tang Z.Y., Wang X.W. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. Gastroenterology 2009, 136:1012-1024.
40. Terradillos O., Billet O., Renard C.A., Levy R., Molina T., Briand P., Buendia M.A. The hepatitis B virus X gene potentiates c-myc-induced liver oncogenesis in transgenic mice. Oncogene 1997, 14:395-404.